William Blair Issues Positive Estimate for ZVRA Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Analysts at William Blair increased their Q2 2025 earnings per share (EPS) estimates for Zevra Therapeutics in a report issued on Wednesday, May 14th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($0.09) for the quarter, up from their previous forecast of ($0.17). The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share. William Blair also issued estimates for Zevra Therapeutics' Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.29) EPS.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.15. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The firm had revenue of $20.40 million for the quarter, compared to analyst estimates of $16.96 million. During the same quarter in the prior year, the company earned ($0.40) EPS.

A number of other brokerages have also recently weighed in on ZVRA. HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a report on Thursday, March 13th. Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, May 14th. Canaccord Genuity Group upped their price objective on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a research report on Thursday, March 13th. Guggenheim increased their price objective on Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, March 13th. Finally, JMP Securities set a $18.00 target price on Zevra Therapeutics in a report on Wednesday, March 12th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $22.29.

Zevra Therapeutics Trading Down 3.4%

NASDAQ:ZVRA traded down $0.30 on Monday, reaching $8.61. 774,675 shares of the company's stock were exchanged, compared to its average volume of 639,690. The firm has a market capitalization of $470.79 million, a price-to-earnings ratio of -4.37 and a beta of 1.87. Zevra Therapeutics has a 52-week low of $4.20 and a 52-week high of $9.76. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The business has a fifty day moving average of $7.57 and a 200-day moving average of $8.08.

Institutional Investors Weigh In On Zevra Therapeutics

Large investors have recently modified their holdings of the company. Barclays PLC raised its position in Zevra Therapeutics by 292.6% in the 3rd quarter. Barclays PLC now owns 57,599 shares of the company's stock valued at $399,000 after purchasing an additional 42,926 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of Zevra Therapeutics by 54.6% in the fourth quarter. SG Americas Securities LLC now owns 23,500 shares of the company's stock valued at $196,000 after buying an additional 8,302 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Zevra Therapeutics in the fourth quarter valued at about $94,000. Rhumbline Advisers boosted its stake in shares of Zevra Therapeutics by 18.4% during the fourth quarter. Rhumbline Advisers now owns 68,053 shares of the company's stock worth $568,000 after buying an additional 10,573 shares during the period. Finally, IFG Advisors LLC grew its holdings in shares of Zevra Therapeutics by 10.0% during the fourth quarter. IFG Advisors LLC now owns 29,050 shares of the company's stock worth $242,000 after buying an additional 2,650 shares during the last quarter. 35.03% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Zevra Therapeutics

In other news, Director John B. Bode purchased 10,000 shares of the company's stock in a transaction that occurred on Wednesday, March 19th. The shares were purchased at an average price of $7.96 per share, for a total transaction of $79,600.00. Following the purchase, the director now directly owns 40,000 shares of the company's stock, valued at $318,400. This represents a 33.33% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.40% of the company's stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.